CONSENT AGREEMENT BETWEEN - State Medical Board of Ohio ...

Matter of Kyle Elliott Hoogendoorn, D.P.M. Page 51
educational experience, and I have a constant referral source for chronic
painful conditions of the foot and ankle only.
(Tr. at 2519-2520)
117. Dr. Hoogendoorn testified that, since completing his fellowship, he has developed a “niche
practice” treating chronic podiatric pain. Dr. Hoogendoorn further testified that it is a
referral-based practice from other physicians, allopaths, osteopaths, and podiatrists.
(Tr. at 2528-2529)
FINDINGS OF FACT
1. From in or about 2000 to in or about 2001, Kyle Elliott Hoogendoorn, D.P.M., undertook
the treatment of nineteen patients 14 as identified on a confidential Patient Key. During the
period in or about August 2000 through in or about November 2001, Dr. Hoogendoorn:
(a) Administered chemoneurolytic and other injections into the splenius capitis, levator
scapulae, trapezius, superior trapezius, cervical erector spinae, thoracic erector spinae,
lumbar erector spinae, latissimus dorsi, paraspinal, and/or rhomboid muscles, and/or
the intraspinous ligament, and/or greater trochanter, and/or gluteal area of Patients 1-
5, 7-9(6-8), 11(9), 14(12), 17(13), and 21-22(16-17).
The evidence is insufficient to support a finding that Dr. Hoogendoorn administered
chemoneurolytic or other injections to Patient 20.
Further, the evidence is insufficient to support a finding that Dr. Hoogendoorn
administered chemoneurolytic or other injections into a zygapophyseal joint of any
patient.
(b) Prescribed controlled and noncontrolled medications, including, but not limited to,
Nicotrol, Wellbutrin, Neurontin, Propranolol, Vioxx, Zyprexa, Ultram, OxyContin,
Clonazepam, Duragesic, Depakote, Senokot, Trazadone, hydrocodone, methadone,
Transderm Scop, Celebrex, Zanaflex, Catapres, Zithromax, propoxyphene, oxazepam
and/or methylphenidate to Patients 2, 7(6), 11-14(9-12), 18(14), 20(15), 23(18), and
24(19) for the treatment of non-podiatric conditions.
2. The Respondents presented evidence that, during the period in question, Dr. Hoogendoorn
had been engaged in a pain medicine fellowship run by Dr. Leak. Although the wisdom of
a podiatrist engaging in such a fellowship may be questionable, the evidence shows that it
is more likely than not that the fellowship at PCC was a legitimate fellowship. Moreover,
the Respondents presented convincing evidence that, in January 2002, Dr. Leak’s
fellowship program received approval as a podiatric fellowship by the Council for Podiatric
14 Patient numbers in this section are referred to by their number in the Master Patient Key. If the patient number on
Dr. Hoogendoorn’s patient key differed, that patient number is noted in parentheses. See Board Exhibit I.